Loading clinical trials...

RECRUITING

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

NCT06549413•M.D. Anderson Cancer Center

Summary

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

Detailed Description

PRIMARY OBJECTIVES: I. Evaluate the ability of 18F-FSPG PET imaging to detect tumors in patients with esophageal cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\* ≥ 18 years of age
•* Patients with locally advanced esophageal cancer
•* Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
•* Ability to provide written informed consent in accordance with institutional policies
•* Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical

Exclusion Criteria

•\* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
•* Pregnant or lactating females
•* Have an allergy to intravenous contrast
•* eGFR \< 30

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

August 23, 2023

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

February 19, 2026

Enrollment

ESTIMATED participants

Conditions

Esophageal Carcinoma

Interventions

Non-Interventional Study

OTHER

Contacts

Steven H Lin, MD, PHD

CONTACT

713-563-2300 shlin@mdanderson.org

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial Carcinoma+25 more

View study

RECRUITING

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

NCT00991094

Breast CarcinomaEsophageal Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Inclusion Criteria

Exclusion Criteria

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer